



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 023070-142500US
Client Ref. No.: 2004-168-1
Customer No.: 20350

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On

July 8, 2004

TOWNSEND and TOWNSEND and CREW LLP

By:

Patricia Andrus

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HAMMOCK *et al.*

Application No.: 10/815,425

Filed: March 31, 2004

For: USE OF CIS-
EPOXYEICOSANTRIENOIC ACIDS
AND INHIBITORS OF SOLUBLE
EPOXIDE HYDROLASE TO REDUCE
PULMONARY INFILTRATION BY
NEUTROPHILS

Confirmation No. 8475

Examiner: Not yet assigned

Art Unit: Not yet assigned

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notice to File Missing Parts of Nonprovisional Application mailed May 18, 2004, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Appl. No. 10/815,425

Amdt. dated July 8, 2004

Reply to Notice to File Missing Parts of May 18, 2004

PATENT

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 4 of this paper.